Literature DB >> 30139779

Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD.

Aili L Lazaar1, Bruce E Miller1, Maggie Tabberer2, John Yonchuk1, Nancy Leidy3, Claire Ambery2, Jackie Bloomer4, Henrik Watz5, Ruth Tal-Singer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30139779     DOI： 10.1183/13993003.01020-2018

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  16 in total

1.  The role of CXCR2 in acute inflammatory responses and its antagonists as anti-inflammatory therapeutics.

Authors:  Xiaoyu Zhang; Rongxia Guo; Hiroto Kambara; Fengxia Ma; Hongbo R Luo
Journal:  Curr Opin Hematol       Date:  2019-01       Impact factor: 3.284

2.  Use of the Evaluating Respiratory Symptoms™ in COPD as an Outcome Measure in Clinical Trials: A Rapid Systematic Review.

Authors:  Donald M Bushnell; Rozanne Wilson; Florian S Gutzwiller; Nancy K Leidy; Carolina Hache; Chau Thach; Claus F Vogelmeier
Journal:  Chronic Obstr Pulm Dis       Date:  2021-10-28

Review 3.  Chemokine Receptor Antagonists: Role in Oncology.

Authors:  Sean Kraus; Thomas Kolman; Austin Yeung; Dustin Deming
Journal:  Curr Oncol Rep       Date:  2021-09-04       Impact factor: 5.075

4.  Improved Decision-Making Confidence Using Item-Based Pharmacometric Model: Illustration with a Phase II Placebo-Controlled Trial.

Authors:  Carolina Llanos-Paez; Claire Ambery; Shuying Yang; Maggie Tabberer; Misba Beerahee; Elodie L Plan; Mats O Karlsson
Journal:  AAPS J       Date:  2021-06-02       Impact factor: 4.009

5.  Blood neutrophil counts are associated with exacerbation frequency and mortality in COPD.

Authors:  Mike Lonergan; Alison J Dicker; Megan L Crichton; Holly R Keir; Melissa K Van Dyke; Hana Mullerova; Bruce E Miller; Ruth Tal-Singer; James D Chalmers
Journal:  Respir Res       Date:  2020-07-01

6.  Efficacy and Safety of Danirixin (GSK1325756) Co-administered With Standard-of-Care Antiviral (Oseltamivir): A Phase 2b, Global, Randomized Study of Adults Hospitalized With Influenza.

Authors:  Anuradha Madan; Shuguang Chen; Phillip Yates; Michael L Washburn; Grace Roberts; Andrew J Peat; Yu Tao; Michael F Parry; Otis Barnum; Micah T McClain; Sumita Roy-Ghanta
Journal:  Open Forum Infect Dis       Date:  2019-04-03       Impact factor: 3.835

Review 7.  Chemokines in COPD: From Implication to Therapeutic Use.

Authors:  Pauline Henrot; Renaud Prevel; Patrick Berger; Isabelle Dupin
Journal:  Int J Mol Sci       Date:  2019-06-06       Impact factor: 5.923

8.  CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixin.

Authors:  Holly R Keir; Hollian Richardson; Christina Fillmore; Amelia Shoemark; Aili L Lazaar; Bruce E Miller; Ruth Tal-Singer; James D Chalmers; Divya Mohan
Journal:  ERJ Open Res       Date:  2020-11-10

Review 9.  Targeting Cytokines as Evolving Treatment Strategies in Chronic Inflammatory Airway Diseases.

Authors:  Jaleesa Garth; Jarrod W Barnes; Stefanie Krick
Journal:  Int J Mol Sci       Date:  2018-10-30       Impact factor: 5.923

10.  CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial.

Authors:  Aili L Lazaar; Bruce E Miller; Alison C Donald; Thomas Keeley; Claire Ambery; John Russell; Henrik Watz; Ruth Tal-Singer
Journal:  Respir Res       Date:  2020-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.